<SUBMISSION>
<SECRELEASE-DATETIME> 20220616-065311 ⇐ Metadata from SEC Info (ET)
<SECWEBSITE-DATETIME> 20220616-065308 ⇐ Metadata from SEC Info (ET)
<ACCEPTANCE-DATETIME> 20220616-065230 ⇐ Filing accepted by SEC (ET)
<ACCESSION-NUMBER> 0001193125-22-175138
<TYPE> 424B5
<PUBLIC-DOCUMENT-COUNT> 5
<FILING-DATE> 20220616
<DATE-OF-FILING-DATE-CHANGE> 20220616
|
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME> Akero Therapeutics, Inc.
<CIK> 0001744659
<ASSIGNED-SIC> 2834
<IRS-NUMBER> 000000000
<STATE-OF-INCORPORATION> DE
<FISCAL-YEAR-END> 1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE> 424B5
<ACT> 33
<FILE-NUMBER> 333-256229
<FILM-NUMBER> 221019305
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1> 601 GATEWAY BOULEVARD, SUITE 350
<CITY> SOUTH SAN FRANCISCO
<STATE> CA
<ZIP> 94080
<PHONE> 650-487-6488
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1> 601 GATEWAY BOULEVARD, SUITE 350
<CITY> SOUTH SAN FRANCISCO
<STATE> CA
<ZIP> 94080
</MAIL-ADDRESS>
</FILER>
|
<DOCUMENT>
<TYPE> 424B5
<SEQUENCE> 1
<FILENAME> d339101d424b5.htm
<DESCRIPTION> 424B5
<TEXT>
<HTML>
Show <HTML>: 3,039 lines (widest: 356 characters) - 346K bytes
</TEXT>
</DOCUMENT>
|
<DOCUMENT>
<TYPE> EX-FILING FEES
<SEQUENCE> 2
<FILENAME> d339101dexfilingfees.htm
<DESCRIPTION> EX-FILING FEES
<TEXT>
<HTML>
Show <HTML>: 374 lines (widest: 249 characters) - 33K bytes
</TEXT>
</DOCUMENT>
|
<DOCUMENT>
<TYPE> GRAPHIC
<SEQUENCE> 3 ⇐ Not a Document/Exhibit
<FILENAME> g339101g01a53.jpg
<DESCRIPTION> GRAPHIC
<TEXT>
Show <TEXT>: 1,375 lines (Unix-to-Unix encoding) - 84K bytes
</TEXT>
</DOCUMENT>
|
<DOCUMENT>
<TYPE> GRAPHIC
<SEQUENCE> 4 ⇐ Not a Document/Exhibit
<FILENAME> g339101g05a05.jpg
<DESCRIPTION> GRAPHIC
<TEXT>
Show <TEXT>: 1,730 lines (Unix-to-Unix encoding) - 104K bytes
</TEXT>
</DOCUMENT>
|
<DOCUMENT>
<TYPE> GRAPHIC
<SEQUENCE> 5 ⇐ Not a Document/Exhibit
<FILENAME> g339101g23a23.jpg
<DESCRIPTION> GRAPHIC
<TEXT>
Show <TEXT>: 1,278 lines (Unix-to-Unix encoding) - 78K bytes
</TEXT>
</DOCUMENT>
|
</SUBMISSION> |
| ↑Top |
